These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Matsuki E; Younes A Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488 [TBL] [Abstract][Full Text] [Related]
4. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Villasboas JC; Ansell SM Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822 [TBL] [Abstract][Full Text] [Related]
6. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases. de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173 [TBL] [Abstract][Full Text] [Related]
7. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390 [TBL] [Abstract][Full Text] [Related]
9. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889 [TBL] [Abstract][Full Text] [Related]
11. Nivolumab in the Treatment of Hodgkin Lymphoma. Ansell SM Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581 [TBL] [Abstract][Full Text] [Related]
12. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review. Dada R Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203 [TBL] [Abstract][Full Text] [Related]
13. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response. Ansell SM Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261 [TBL] [Abstract][Full Text] [Related]
17. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021 [TBL] [Abstract][Full Text] [Related]
18. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. Vardhana S; Cicero K; Velez MJ; Moskowitz CH Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490 [TBL] [Abstract][Full Text] [Related]
19. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation. Steinerová K; Jindra P; Lysák D; Karas M Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632 [TBL] [Abstract][Full Text] [Related]
20. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Qin Q; Nan X; Miller T; Fisher R; Teh B; Pandita S; Farach AM; Pingali SR; Pandita RK; Butler EB; Pandita TK; Iyer SP Radiat Res; 2018 Sep; 190(3):322-329. PubMed ID: 29949442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]